DNAP news:
The University of Miami and DNAPrint Present Novel Chemopredictive Results at
33rd Annual SGO Meeting
Business Editors/Health & Medical Writers
MIAMI--(BUSINESS WIRE)--March 19, 2002--
Novel Genomics Approach Identified Predictive
Markers for Variable Taxol Response
University of Miami doctors presented today the successful results
of an ongoing pharmacogenomics study with DNAPrint genomics, Inc.
(OTCBB:DNAP) at the 33rd annual Society for Gynecological Oncology in
Miami, FL.
Approximately 500 Gynecological Oncologists were presented with an
original set of genetic determinants for variable paclitaxel response
during the first line of chemotherapy for Ovarian Cancer.
The results have implications for dramatically reducing the
failure rate of first-line chemotherapy for Ovarian Cancer patients.
Roughly 30% of patients fail to respond to combination paclitaxel and
carboplatin chemotherapy, which is the current FDA approved first-line
treatment for Ovarian Cancer. Non-response during the first-line of
chemotherapy is linked with poor prognosis and reduced patient
survival.
University of Miami physicians monitored paclitaxel response in a
group of Ovarian Cancer patients over the past year and provided these
data to DNAPrint for genomics study. DNAPrint scientists used an
innovative heuristic method with geometrical projection to identify
and model proprietary "eigengenotypes," or population based vectors of
genome information, that serve as features for variable paclitaxel
response. The team found that certain paclitaxel response
"eigengenotypes" were strongly predictive for first-line chemotherapy
response in Ovarian Cancer patients. Data was shown that suggests that
by screening patient genomes for these "eigengenotypes" prior to the
commencement of chemotherapy, most non-responders could be flagged and
re-directed towards doses and/or alternative chemotherapy more
appropriate for their genetic constitution. The team plans to
prospectively validate and market the predictive genetic test, called
OVANOME, for a personalization of chemotherapy and an improvement in
the overall first-line response rate for Ovarian Cancer chemotherapy.
DNAPrint is the only company in the world constructing a database
of "eigengenotypes" useful for predicting response to the worlds
leading prescription medications. Earlier this year, DNAPrint filed
patent for an innovative approach for "eigengenotype"-based
conceptualization from high-density genomics data sets in geometric
space. The University of Miami is a pioneer in the diagnosis and
therapy of gynecological cancers through the application of innovative
genomics technologies.
Paclitaxel is sold by the Brisol-Myers Squibb Corporation
(NYSE:BMY) under the registered trademark Taxol(R). In 1998, the FDA
approved semisynthetic TAXOL in combination with cisplatin, for the
first-line treatment of advanced carcinoma of the ovary.
About the Unversity of Miami School of Medicine and Familial
Breast and Ovarian Cancer Center.
The University of Miami School of Medicine, founded in 1952, has
already established a research enterprise which the National
Institutes of Health ranks in the top 30 percent of the country's
125 medical schools with regards to research funding awarded. The
University of Miami Familial Breast and Ovarian Cancer Center
maintains a patient registry, conducts research, and educates
physicians and the public. The center treats over 300 Ovarian Cancer
patients per year with state-of-the-art treatments.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical and
statistical modeling, programming and molecular genetics. Our quest is
to become the leader in the development of complex pharmacogenomics
classifiers for a personalization of drug prescription. The Company is
traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP.
For more information about the company, please visit
http://www.dnaprint.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act as amended. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected, including, but not limited to,
uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory
approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such
statements are based.
--30--gaa/mi*
CONTACT: DNAPrint genomics, Inc., Miami
Investor Contact: Carrie Castillo, 941/366-3400
ccastillo@dnaprint.com
or
Media Contact: Russell LaMontagne, 212/219-0800
russell@corinthgroup.com
KEYWORD: FLORIDA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
SOURCE: DNAPrint genomics, Inc.
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com
Mar-19-2002 15:35 GMT
Symbols:
US;DNAP
Source BW Business Wire
Categories:
MST/R/US/FL MST/I/BTC MST/I/MTC MST/I/DRG
News 
Market Data 
Discover 
AI
